Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Outlook Therapeutics (OTLK) Equity Ratio (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Equity Ratio for 8 consecutive years, with 2.11 as the latest value for Q4 2025.

  • Quarterly Equity Ratio rose 28.53% to 2.11 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2.11 through Dec 2025, up 28.53% year-over-year, with the annual reading at 1.73 for FY2025, N/A changed from the prior year.
  • Equity Ratio for Q4 2025 was 2.11 at Outlook Therapeutics, down from 1.73 in the prior quarter.
  • The five-year high for Equity Ratio was 1.66 in Q2 2025, with the low at 2.96 in Q4 2024.